68860-35-5Relevant articles and documents
Zinc (II) complex with a cationic Schiff base ligand: Synthesis, characterization, and biological studies
Lee, Sze Koon,Tan, Kong Wai,Ng, Seik Weng,Ooi, Kah Kooi,Ang, Kok Pian,Abdah, Md Akim
, p. 101 - 108 (2014)
A cationic Schiff base ligand, TSB (L) and its Zn (II) complex (1) were synthesized and characterized by using CHN, 1H-NMR, FT-IR, UV, LC-MS, and X-ray methods. Their ability to inhibit topoisomerase I, DNA cleavage activities, and cytotoxicity
Benzimidazole derivative and 8-hydroxyquinoline derivative cadmium complex dye sensitizer as well as preparation method and application thereof
-
, (2021/01/24)
The invention relates to a D (-A-pi-A) 2 type benzimidazole derivative and 8-hydroxyquinoline derivative cadmium complex dye sensitizer (BDTT-bi-Cd) as shown in a formula 1 as well as a preparation method and application of the BDTT-bi-Cd. The dye sensitizer is a D (-A-pi-A) 2 type complex synthesized by reacting benzimidazole containing functional groups such as an auxiliary electron acceptor (A), a pi bridge, a main electron acceptor (A) and an anchoring group with a 8-hydroxyquinoline derivative cadmium complex and an electron donor (D) benzodithiophene bithiophene (BDTT) through a Heck coupling reaction. Experiments show that the photovoltaic performance test of a dye-sensitized solar cell with the BDTT-bi-Cd as the dye sensitizer shows good effects that the photoelectric conversion efficiency (PCE) reaches 8.40%, the dye thermal decomposition temperature reaches 320 DEG C or above, the thermal stability is high, the requirements of photovoltaic materials can be met, and the complex dye sensitizer has a certain prospect in the aspect of development and application of the dye-sensitized solar cell. The structure of the complex BDTT-bi-Cd shown in the formula 1 is shown in the specification.
Sterol regulatory element binding protein and acidic nucleoplasm DNA binding protein-1 inhibitor, preparation method and application thereof
-
, (2020/07/13)
The invention discloses a compound which is shown as formula I and can inhibit sterol regulatory element binding protein (Srebp) and acidic nucleoplasm DNA binding protein-1 (And-1, WDHD1), a preparation method and application thereof. RT-PCR (reverse transcription-polymerase chain reaction) and immunoblotting experiments show that the compound can remarkably reduce the expression of a Srebp downstream gene SCD-1 and inhibit the activity of And-1 protein. Further experiments show that the compound has a proliferation inhibition effect on various tumor cells. The compound shown as formula I isexpected to become a novel anti-tumor drug and a tumor chemoradiotherapy sensitizing drug.